Metastatic Hepatocellular Carcinoma Clinical Trials
32 clinical trials for Metastatic Hepatocellular Carcinoma across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers — RECRUITING · NA
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer — RECRUITING · PHASE2
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing — RECRUITING · PHASE1
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial — RECRUITING · PHASE1
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
- Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations — RECRUITING · PHASE1
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. — RECRUITING · PHASE1
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
- A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma — RECRUITING · PHASE1
- Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies — RECRUITING · PHASE1
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer — RECRUITING · PHASE2
- A Phase 2/3, Randomized Study to Evaluate the Optimized dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) who have not previously received systemic treatment — TERMINATED · PHASE3
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab — TERMINATED · PHASE2
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver — ACTIVE_NOT_RECRUITING · PHASE2
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer — TERMINATED · PHASE1
- Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer — NOT_YET_RECRUITING
- Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy — NOT_YET_RECRUITING
- Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer — NOT_YET_RECRUITING
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
- Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma — SUSPENDED · PHASE1
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
- Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer — COMPLETED · PHASE2
- A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective — COMPLETED · PHASE1
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma — COMPLETED · PHASE2
- Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment — COMPLETED · PHASE2
- A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma — WITHDRAWN · PHASE1
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) — COMPLETED · PHASE1
- Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral — WITHDRAWN · PHASE2
- Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma — OTHER · PHASE2
Refine this search